Sanaria is a biotechnology company developing vaccines protective against malaria and related products for use in malaria research. With Sanarias vaccines based on the use of the sporozoite stage of the Plasmodium parasite as immunogen, the firm has developed the technology to grow and harvest large quantities of aseptic, purified Plasmodium sporozoites and formulate them for use in vaccines for human use. Sanaria's initial candidate vaccine is called Sanaria PfSPZ, and uses radiation attenuated Plasmodium falciparum sporozoites as immunogen. Sanaria is developing other vaccines, including Sanaria CVac, which uses unattenuated sporozoites in the presence of antimalarial drugs as immunogen; genetically attenuated sporozoites as immunogen, and other species of Plasmodium in all these formulations.
